Supreme Court Asked to Reinstate Mail-Order Access to Abortion Pill Mifepristone 
CDC Confirms U.S. Ebola Case Linked to Congo Outbreak as Travel Restrictions Tighten 
US Plans Kenya Ebola Quarantine Facility Amid Congo Outbreak 
Nike CFO Shake-Up Fuels Concerns Over Turnaround Strategy 
Why the future of marijuana legalization remains hazy despite high public support 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
Trump Orders DOJ Investigation Into Exxon, Chevron Over High Gas Prices 
AstraZeneca Q1 2026 Earnings Surge on Strong Oncology and Rare Disease Drug Sales 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
Samsung and SK Hynix Shares Jump After Micron Earnings Boost AI Chip Optimism 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Novo Nordisk Raises 2026 Outlook on Strong Wegovy Demand 
Alibaba Shares Fall After Anthropic Alleges Massive AI Model Distillation Campaign 
RFK Jr. Spokesman Resigns Over Trump Administration’s Flavored E-Cigarette Policy 
Johns Hopkins University Lays Off 110 Employees as Federal Research Funding Declines 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
Drugmaker Merck has partnered with Daiichi Sankyo, under which it will pay $5.5 billion to develop three candidate cancer drugs jointly. This deal could be worth up to $22 billion for Daiichi Sankyo, depending on the success of the therapies.
Shares of Daiichi Sankyo soared by 14.4% in Tokyo, marking their largest gain in over a year. Merck also saw a rise of 1.6% in morning trading.
Ambitious Revenue Target for Daiichi Sankyo's Oncology Business
According to Reuters, Daiichi Sankyo has set a revenue target of at least 900 billion yen ($6 billion) for its oncology business by the fiscal year ending March 31, 2026. This would represent an impressive five-fold increase over three years.
Investopedia noted that the three-drug candidates to be developed with Merck fall into the antibody-drug conjugates (ADC) class, with various stages of clinical development for treating multiple solid cancer tumors. Unlike conventional chemotherapy, ADCs are designed to target cancer cells, minimizing damage to healthy cells specifically.
"One of the changes in the external environment is intensifying competition in ADC development," Daiichi Sankyo CEO Sunao Manabe said, describing the company's decision to seek a partner.
Promising Commercial Revenue Potential
The drug candidates - patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan - hold significant worldwide commercial revenue potential for both companies by the mid-2030s, according to Merck and Daiichi Sankyo.
Under the agreement, Merck and Daiichi Sankyo will jointly develop and potentially commercialize the drug candidates globally, except in Japan, where Daiichi Sankyo will retain exclusive rights. Daiichi Sankyo will be responsible for manufacturing and supply.
Merck Gains Access to Daiichi Sankyo's Expertise in the ADC Space
The partnership allows Merck to tap into Daiichi Sankyo's leadership status in the ADC field. Analysts believe this collaboration will strengthen Merck's cancer drug portfolio, particularly as its top-selling Keytruda faces patent expiration at the end of the decade.
In return for the collaboration, Merck will make an upfront payment of $4 billion to Daiichi Sankyo, followed by $1.5 billion in continuation payments over the next two years. Additionally, Merck may pay up to $16.5 billion based on future sales milestones, amounting to $5.5 billion for each product.
Daiichi Sankyo has six ADC candidates in its pipeline, including two jointly developed with AstraZeneca. However, this week's disappointing data abstract on the late-stage trial of datopotamab deruxtecan, developed with AstraZeneca, has impacted analysts' expectations.
Photo: Merck Media
